Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.

American journal of hematology - 1 Dec 2022

Venugopal Sangeetha, DiNardo Courtney D, Loghavi Sanam, Qiao Wei, Ravandi Farhad, Konopleva Marina, Kadia Tapan, Bhalla Kapil, Jabbour Elias, Issa Ghayas C, Macaron Walid, Daver Naval, Borthakur Gautam, Montalban-Bravo Guillermo, Yilmaz Musa, Patel Keyur P, Kanagal-Shamanna Rashmi, Chien Kelly, Maiti Abhishek, Kantarjian Hagop, Short Nicholas J

Abstract excerpt

RUNX1-mutated (mRUNX1) acute myeloid leukemia (AML) has historically been associated with poor outcomes in the setting of conventional chemotherapy. The prognostic impact of mRUNX1 AML is not well-established in the current era of lower-intensity treatment regimens incorporating venetoclax. We retrospectively analyzed 907 patients with newly diagnosed AML, including 137 patients with mRUNX1 AML, who underwent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factor Alpha 2 Subunit

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 36087091
DOI: 10.1002/ajh.26724

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.PMID 36087091Read ↗

Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.Semantic proximity Read ↗

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching studySemantic proximity Read ↗

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.Semantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.Semantic proximity Read ↗

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese PatientsSemantic proximity Read ↗

Venetoclax and hypomethylating agents in FLT3 ‐mutated acute myeloid leukemiaSemantic proximity Read ↗

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.Semantic proximity Read ↗

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.Semantic proximity Read ↗

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.Semantic proximity Read ↗

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemiaSemantic proximity Read ↗

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.